IMPACT OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL ON MORTALITY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Abstract

Patients with chronic obstructive pulmonary disease (COPD) have a 3-year mortality rate up to 37%, 2–6 times higher than the general population. The IMPACT trial demonstrated a significant reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol (FF / UMEC / VI) versus UMEC / VI in patients with COPD. It was reported vital status data for 99.6% of the intention-to-treat population (n = 10 355), documenting 98 (2.36%) deaths on FF / UMEC / VI, 109 (2.64%) on FF / VI, and 66 (3.19%) on UMEC / VI. For FF / UMEC / VI, the hazard ratio for death was 0.72 (95% confidence interval, 0.53–0.99; p = 0.042) versus UMEC / VI and 0.89 (95% confidence interval, 0.67–1.16; p = 0.387) versus FF / VI. In this analysis, FF / UMEC / VI triple therapy reduces the risk of all-cause mortality in patients with symptomatic COPD and a history of exacerbations.